> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Merck BioReliance Facility Passes FDA Inspection
- URL: https://www.fdaweb.com/merck-bioreliance-facility-passes-fda-inspection/
- Published: 2017-10-19T12:00:00.000Z
- Updated: 2026-09-14T22:57:03.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139918

Merck says that its Carlsbad, CA, manufacturing facility to produce BioReliance viral and gene therapy products has completed and passed both an FDA and a European Medicines Agency inspection. A company [statement](https://www.emdgroup.com/en/news/carlsbad-2017-10-19.html?ref=fdaweb.com) says the Carlsbad facility provides contract development and manufacturing services that can contribute to a more efficient delivery of lifesaving therapies to market.

The company says the inspections will enable one of its key customers to launch in the U.S. and Europe its novel gene therapy that is currently under review by both agencies. “The inspections were significant milestones in the approval process to obtain the licenses necessary to manufacture the gene therapy as a commercial product,” Merck says.